7 studies found for:    MEDI551
Show Display Options
Rank Status Study
1 Recruiting Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
Condition: Multiple Sclerosis, Relapsing Forms
Interventions: Biological: MEDI-551 IV;   Biological: MEDI-551 SC;   Drug: Placebo IV;   Drug: Placebo SC
2 Active, not recruiting A Study of the Safety and Tolerability of MEDI-551 in Scleroderma
Condition: Scleroderma
Interventions: Biological: MEDI-551;   Biological: Placebo;   Other: Placebo
3 Recruiting Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Condition: Myeloma
Intervention: Drug: Lenalidomide, Dexamethasone, and MEDI-551
4 Active, not recruiting A Phase 1, Dose-escalation Study of MEDI-551 in Japanese Adult Patients With Relapsed or Refractory Advanced B-cell Malignancies
Conditions: Blood Cancer;   Advanced B Cell Malignancies
Intervention: Drug: MEDI-551
5 Recruiting A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
Condition: B-cell Malignancies
Interventions: Drug: MEDI-551;   Drug: Rituximab
6 Recruiting A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: MEDI-551;   Drug: Rituximab;   Drug: Bendamustine
7 Recruiting A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Drug: MEDI-551;   Drug: Rituximab;   Drug: ICE;   Drug: DHAP;   Procedure: Autologous Stem Cell Transplant (ASCT)

Indicates status has not been verified in more than two years